选择性5-羟色胺再摄取抑制剂治疗无效抑郁症患者换用文拉法辛与锂强化治疗的对照研究  

A controlled study on venlafaxine and lithium augmentation treatment in major depressive disorder with non-responder to selective serotonin reuptake inhibitors

作　　者：寻知元[1] 张国双[1] 江芮[1] 吕浩[1] 

机构地区：[1]天津市安定医院,300222

出　　处：《临床精神医学杂志》2013年第1期42-44,共3页Journal of Clinical Psychiatry

摘　　要：目的:比较文拉法辛与碳酸锂强化治疗对选择性5-羟色胺再摄取抑制剂(SSRI)治疗无效的抑郁症患者的疗效和安全性。方法:将SSRI治疗无效的抑郁症患者随机分为两组,分别予文拉法辛替换SSRI治疗和加用碳酸锂强化治疗。在治疗前及治疗1、2、4、8周采用汉密尔顿抑郁量表(HAMD)评分评定临床疗效。采用治疗中出现的症状量表(TESS)评定药物安全性。结果:文拉法辛组治疗痊愈率为51.1%,锂强化组治疗痊愈率为28.9%,两组痊愈率差异有统计学意义(P<0.05)。结论:SSRI治疗无效的抑郁症患者换用文拉法辛的疗效优于碳酸锂强化治疗。Objective：To compare the efficacy and safety of venlafaxine and augmentation treatment of lithium for depressive patients who had not responded to selective serotonin reuptake inhibitors （SSRI）. Method：Patients who had not responded to SSRI were divided into two groups randomly and treated with ven- lafaxine substituting SSRI and augmentation treatment of lithium respectively. At the beginning and at the end of the lth 2th and 4th and 8th week the efficacy was evaluated by Hamilton rating scale for depression （ HAMD）, the safety was evaluated with the treatment emergent symptom scale （TESS）. Results ： The proportion of pa- tients who showed full remission was 51.1% in venlafaxine group and 28.9% in augmentation treatment of lith- ium group. There was significant difference of efficacy between the two groups （ P 〈 0.05 ）. Conclusion ： Ven- lafaxine substituting SSRI is more effective than augmentation treatment of lithium in the treatment of patients who had not responded to SSRI.

关 键 词：抑郁症 选择性5-羟色胺再摄取抑制剂 文拉法辛 碳酸锂 

分 类 号：R749.4[医药卫生—神经病学与精神病学]